These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21104470)

  • 21. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.
    Russo A; Rizzo S; Bronte G; Silvestris N; Colucci G; Gebbia N; Bazan V; Fulfaro F
    Oncology; 2009; 77 Suppl 1():57-68. PubMed ID: 20130433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
    Song QB; Wang Q; Hu WG
    World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis.
    Bouchahda M; Karaboué A; Saffroy R; Innominato P; Gorden L; Guettier C; Adam R; Lévi F
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):605-9. PubMed ID: 20361188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.
    Baynes RD; Gansert J
    Am J Ther; 2009; 16(6):554-61. PubMed ID: 19352138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis.
    Cejas P; López-Gómez M; Aguayo C; Madero R; de Castro Carpeño J; Belda-Iniesta C; Barriuso J; Moreno García V; Larrauri J; López R; Casado E; Gonzalez-Barón M; Feliu J
    PLoS One; 2009 Dec; 4(12):e8199. PubMed ID: 20020061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
    De Roock W; De Vriendt V; Normanno N; Ciardiello F; Tejpar S
    Lancet Oncol; 2011 Jun; 12(6):594-603. PubMed ID: 21163703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
    Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical significance and the handling of KRAS testing on metastatic colorectal cancer].
    Kawamoto Y; Yoshino T
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():346-50. PubMed ID: 22213982
    [No Abstract]   [Full Text] [Related]  

  • 29. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
    Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The role of KRAS gene mutation testing in colorectal cancer--a predictive biomarker of response to EGFR inhibitors therapy].
    Rako I; Jakić-Razumović J; Caban D; Sertić J; Katalinić D; Golem H; Plestina S
    Lijec Vjesn; 2011; 133(11-12):403-7. PubMed ID: 22329297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
    Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
    J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
    Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
    Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].
    Nozawa K; Watanabe T
    Gan To Kagaku Ryoho; 2010 May; 37(5):791-4. PubMed ID: 20495308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR and KRAS in colorectal cancer.
    Markman B; Javier Ramos F; Capdevila J; Tabernero J
    Adv Clin Chem; 2010; 51():71-119. PubMed ID: 20857619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
    Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
    Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.
    Perkins G; Pilati C; Blons H; Laurent-Puig P
    Pharmacogenomics; 2014 May; 15(7):1043-52. PubMed ID: 24956256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
    J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular differences in the KRAS gene mutation between a primary tumor and related metastatic sites - case report and a literature review.
    Kosakowska EA; Stec R; Charkiewicz R; Skoczek M; Chyczewski L
    Folia Histochem Cytobiol; 2010 Dec; 48(4):597-602. PubMed ID: 21478103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
    Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M
    Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.